ResMed (NYSE:RMD) Stock Price Target Raised at Citigroup

ResMed (NYSE:RMD) had its target price increased by Citigroup from $240.00 to $270.00 in a report published on Friday,Benzinga reports. Citigroup currently has a neutral rating on the medical equipment provider’s stock.

Other analysts have also recently issued reports about the company. Rothschild & Co Redburn initiated coverage on ResMed in a research report on Wednesday, August 19th. They issued a “neutral” rating and a $230.00 target price for the company. Mizuho set a $270.00 price target on ResMed in a research report on Friday. UBS Group reiterated a “buy” rating and issued a $300.00 price objective on shares of ResMed in a research note on Tuesday, July 21st. Royal Bank Of Canada increased their price objective on ResMed from $262.00 to $288.00 and gave the company an “outperform” rating in a report on Friday. Finally, Piper Sandler lowered their target price on shares of ResMed from $233.00 to $225.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Seven research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $253.69.

ResMed Price Performance

Shares of RMD opened at $230.76 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.10 and a quick ratio of 2.42. ResMed has a 1-year low of $180.26 and a 1-year high of $277.67. The stock has a market cap of $32.45 billion, a PE ratio of 21.02, a price-to-earnings-growth ratio of 1.55 and a beta of 0.75. The firm has a fifty day moving average price of $231.87 and a 200 day moving average price of $225.43.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, October 29th. The medical equipment provider reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.67 by $0.24. ResMed had a return on equity of 25.90% and a net margin of 27.79%. The company had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.39 billion. During the same quarter last year, the company posted $2.55 earnings per share. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that ResMed will post 12.11 EPS for the current year.

ResMed Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 17th. Investors of record on Thursday, November 12th will be issued a dividend of $0.66 per share. The ex-dividend date of this dividend is Thursday, November 12th. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.1%. ResMed’s dividend payout ratio (DPR) is currently 25.31%.

Insider Buying and Selling

In other news, Director Peter C. Farrell sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $225.00, for a total value of $1,800,000.00. Following the transaction, the director owned 52,773 shares of the company’s stock, valued at approximately $11,873,925. The trade was a 13.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael J. Farrell sold 4,991 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $205.69, for a total value of $1,026,598.79. Following the sale, the chief executive officer owned 466,256 shares of the company’s stock, valued at $95,904,196.64. This trade represents a 1.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 24,343 shares of company stock valued at $5,396,098 over the last quarter. 0.58% of the stock is currently owned by insiders.

Institutional Trading of ResMed

Several hedge funds have recently made changes to their positions in the company. Bell Investment Advisors Inc purchased a new stake in shares of ResMed during the 2nd quarter worth approximately $26,000. Trust Co. of Vermont purchased a new position in ResMed in the 2nd quarter valued at approximately $39,000. Kelleher Financial Advisors purchased a new position in ResMed in the 2nd quarter valued at approximately $47,000. Provenance Wealth Advisors LLC purchased a new position in ResMed in the 3rd quarter valued at approximately $55,000. Finally, Harbor Investment Advisory LLC raised its holdings in ResMed by 82.6% during the second quarter. Harbor Investment Advisory LLC now owns 409 shares of the medical equipment provider’s stock worth $80,000 after purchasing an additional 185 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company’s stock.

Trending Headlines about ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Quarterly results exceeded expectations. ResMed reported fiscal Q1 2027 adjusted earnings of $2.91 per share versus the $2.67 consensus estimate, while revenue rose 5.9% year over year to $1.41 billion, ahead of the $1.39 billion forecast. ResMed fiscal first-quarter results
• Positive Sentiment: Profitability and demand trends improved. Sustained demand for sleep devices, productivity gains and gross-margin expansion supported the earnings beat. EPS increased from $2.55 in the year-ago quarter, and ResMed reported a 26.94% net margin. ResMed earnings and margin growth
• Positive Sentiment: Analysts raised price targets. RBC increased its target from $262 to $288 and assigned an “outperform” rating. KeyCorp raised its target from $267 to $277 with an “overweight” rating, while Wells Fargo lifted its target from $215 to $250 and maintained “equal weight.” Citigroup raised its target from $240 to $270 but retained a “neutral” rating. Analyst target changes
• Neutral Sentiment: ResMed declared a quarterly dividend of $0.66 per share, or $2.64 annualized, representing an approximately 1.1% yield. The dividend supports shareholder returns but is unlikely to be the primary near-term stock catalyst.
• Negative Sentiment: Full-year guidance was unchanged. The lack of an outlook increase may have disappointed investors who expected the earnings beat and improving margins to result in raised expectations. The neutral ratings from Citigroup and Wells Fargo may also limit the impact of the higher price targets. ResMed maintains prior guidance

ResMed Company Profile

ResMed Inc is a medical equipment and software company that develops solutions for sleep-disordered breathing, respiratory conditions and other chronic diseases. The company is best known for its positive airway pressure (PAP) devices used to treat obstructive sleep apnea, along with masks, accessories and related patient support services.

ResMed also provides cloud-connected health technology, including remote-monitoring platforms and software used by healthcare providers, medical equipment suppliers and care organizations.